RJR-2429 is a drug that acts as an agonist at neural nicotinic acetylcholine receptors binding to both the α3β4 and the α4β2 subtypes. RJR-2429 is stronger than nicotine but weaker than epibatidine in most assays and with high affinity for both α3β4 and α4β2 subtypes as well as the less studied α1βγδ subtype.
This page contains content from the copyrighted Wikipedia article "RJR-2429"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
